JP2024504926A5 - - Google Patents

Info

Publication number
JP2024504926A5
JP2024504926A5 JP2023541722A JP2023541722A JP2024504926A5 JP 2024504926 A5 JP2024504926 A5 JP 2024504926A5 JP 2023541722 A JP2023541722 A JP 2023541722A JP 2023541722 A JP2023541722 A JP 2023541722A JP 2024504926 A5 JP2024504926 A5 JP 2024504926A5
Authority
JP
Japan
Prior art keywords
composition according
car
tumor
receptor
dnase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541722A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024504926A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/011648 external-priority patent/WO2022150609A1/en
Publication of JP2024504926A publication Critical patent/JP2024504926A/ja
Publication of JP2024504926A5 publication Critical patent/JP2024504926A5/ja
Pending legal-status Critical Current

Links

JP2023541722A 2021-01-08 2022-01-07 がんの処置のためのデオキシリボヌクレアーゼ酵素と細胞療法の組み合わせ Pending JP2024504926A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163135438P 2021-01-08 2021-01-08
US63/135,438 2021-01-08
US202163148304P 2021-02-11 2021-02-11
US63/148,304 2021-02-11
PCT/US2022/011648 WO2022150609A1 (en) 2021-01-08 2022-01-07 Combination of deoxyribonuclease enzyme and cell therapies for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024504926A JP2024504926A (ja) 2024-02-02
JP2024504926A5 true JP2024504926A5 (cg-RX-API-DMAC7.html) 2025-01-15

Family

ID=82358327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541722A Pending JP2024504926A (ja) 2021-01-08 2022-01-07 がんの処置のためのデオキシリボヌクレアーゼ酵素と細胞療法の組み合わせ

Country Status (5)

Country Link
US (1) US20240050476A1 (cg-RX-API-DMAC7.html)
EP (1) EP4274585A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024504926A (cg-RX-API-DMAC7.html)
CA (1) CA3203945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022150609A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3219838A1 (en) * 2021-05-21 2022-11-24 Dmitry Dmitrievich Genkin Immunomodulation of tumor microenvironment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017302668B9 (en) * 2016-07-28 2023-06-22 Novartis Ag Combination therapies of chimeric antigen receptors and PD-1 inhibitors
AU2019209770B2 (en) * 2018-01-16 2025-07-31 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US12258597B2 (en) * 2018-02-07 2025-03-25 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
US11058724B2 (en) * 2018-10-08 2021-07-13 Neutrolis, Inc. Methods of using DNASE1-like 3 in therapy
CA3219838A1 (en) * 2021-05-21 2022-11-24 Dmitry Dmitrievich Genkin Immunomodulation of tumor microenvironment

Similar Documents

Publication Publication Date Title
JP2022523204A5 (cg-RX-API-DMAC7.html)
Shi et al. Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment
JP2024074801A5 (cg-RX-API-DMAC7.html)
JP2023524047A5 (cg-RX-API-DMAC7.html)
RU2020127887A (ru) Полипептиды транспозазы и их применение
JP2024520676A5 (cg-RX-API-DMAC7.html)
RU2020120411A (ru) Триспецифические связывающие молекулы, направленные против опухолеассоциированных антигенов, и пути их применения
JP2016117766A5 (cg-RX-API-DMAC7.html)
JP2023501722A5 (cg-RX-API-DMAC7.html)
JP2021525731A5 (cg-RX-API-DMAC7.html)
JP2021502104A5 (cg-RX-API-DMAC7.html)
JP2021525509A5 (cg-RX-API-DMAC7.html)
Ponterio et al. Identification of targets to redirect CAR T cells in glioblastoma and colorectal cancer: an arduous venture
EP3578570A1 (en) Multifunctional protein
JP2022545167A5 (cg-RX-API-DMAC7.html)
WO2014138314A1 (en) Oncolytic virus
JP2021500932A5 (cg-RX-API-DMAC7.html)
JP2015530359A5 (cg-RX-API-DMAC7.html)
JP2024521472A5 (cg-RX-API-DMAC7.html)
JP2016519651A5 (cg-RX-API-DMAC7.html)
Zhu et al. Engineering high affinity humanized anti‐p185HER2/anti‐CD3 bispecific F (ab′) 2 for efficient lysis of p185HER2 overexpressing tumor cells
JP2021522208A5 (cg-RX-API-DMAC7.html)
JP2024509095A5 (cg-RX-API-DMAC7.html)
JP2024504926A5 (cg-RX-API-DMAC7.html)
ES2965437T3 (es) Células T modificadas genéticamente resistentes a fármacos y procedimientos de utilización de las mismas